oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 2 )

2019 ( 6 )

2018 ( 12 )

2017 ( 4 )

Custom range...

Search Results: 1 - 10 of 6635 matches for " Porfirio; Jaime Fagundo "
All listed articles are free for downloading (OA Articles)
Page 1 /6635
Display every page Item
Nuevas estrategias en el tratamiento de la leucemia mieloide crónica
Pavón Morán,Valia; Jaime Fagundo,Juan Carlos; Agramonte Llanes,Olga; Hernández Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2007,
Abstract: new therapeutic models have been recommended in the last years to be used in patients with chronic myeloid leukemia (cml) resistant or intolerant to imatinib. most of the models are based on interventions on specific sites of the signal transmission system that the cells used to send information to the nucleus. one of the strategies that has been incorporated is the use of farnesyl transferase inhibitors. therapeutic products that may be administered by oral route, due to the small size of their molecules, have already been identified. at present, there are 4 inhibitors in more advanced stages, mainly the r115777 (zarnestra, tipifarnib). the search for other tretament models gave rise to the appearance of new molecules that may be used to treat the cases of resistance or intolerance to imatinib, such as desatinib and dilotinib. other molecule under experimentation phase is that currently known as pkc 412 (n-benzoylstaurosporine), cgp41251 that is a powerful selective inhibitor of the protein kinase c isoforms . the development of the molecular therapeutics has advanced rapidly and its application to cml has attained very positive results that should increase with the incorporation of the new drugs under study and of those that will certainly emerge in the future
Imatinib en leucemia mieloide crónica
Pavón Morán,Valia; Hernández Ramírez,Porfirio; Jaime Fagundo,Juan Carlos; Agramonte Llanes,Olga;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2005,
Abstract: chronic myeloid leukemia (cml) was the first neoplasia in which it was possible to present a model of genotype that served as a target for a molecular action therapy. the activation of multiple ways of transduction signals in the cells with the bcr-abl gene favors the increase of the cellular proliferation, interferes the apoptosis, and perturbs the interaction with the extracellular matrix and the stroma. the introduction of imatinib in the treatment of cml has modified the evolution and prognosis of this disease. imatinib has proved to have a high level of efficiency associated with a smaller number of adverse reactions on being compared with the regimens based on interferon and hydroxyurea
Nuevas estrategias en el tratamiento de la leucemia mieloide crónica New strategies in the treatment of chronic myeloid leukemia
Valia Pavón Morán,Juan Carlos Jaime Fagundo,Olga Agramonte Llanes,Porfirio Hernández Ramírez
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2007,
Abstract: En los últimos a os se han propuesto nuevos modelos terapéuticos para ser utilizados en pacientes con leucemia mieloide crónica (LMC) resistentes o intolerantes al Imatinib. La mayor parte de estos modelos están basados en intervenciones sobre sitios específicos del sistema de transmisión de se ales que la célula utiliza para hacer llegar información al núcleo. Una de las estrategias incorporadas es el uso de inhibidores de la farnesiltransferasa y ya se han identificado productos terapéuticos factibles de ser utilizados por vía oral, debido al peque o tama o de sus moléculas. Actualmente hay 4 inhibidores en fases más avanzadas, fundamentalmente el R115777 (zarnestra, tipifarnib). La búsqueda de otros modelos de tratamiento dio lugar a la aparición de nuevas moléculas que pudieran ser utilizadas para tratar los casos de resistencia o intolerancia al Imatinib, entre estas el Desatinib y el Dilotinib. Otra molécula en fase de experimentación en casos de resistencia al Imatinib es la conocida actualmente como .PKC 412 (N benzil-estauroporina), CGP41251 que es un potente inhibidor selectivo de las isoformas de la proteincinasa C. El desarrollo de la terapéutica molecular ha avanzado rápidamente y su aplicación en la LMC ha logrado resultados muy positivos que se deben incrementar con la incorporación de los nuevos medicamentos en estudio y de aquellos que seguramente deben aparecer en un futuro New therapeutic models have been recommended in the last years to be used in patients with chronic myeloid leukemia (CML) resistant or intolerant to Imatinib. Most of the models are based on interventions on specific sites of the signal transmission system that the cells used to send information to the nucleus. One of the strategies that has been incorporated is the use of farnesyl transferase inhibitors. Therapeutic products that may be administered by oral route, due to the small size of their molecules, have already been identified. At present, there are 4 inhibitors in more advanced stages, mainly the R115777 (zarnestra, tipifarnib). The search for other tretament models gave rise to the appearance of new molecules that may be used to treat the cases of resistance or intolerance to Imatinib, such as Desatinib and Dilotinib. Other molecule under experimentation phase is that currently known as PKC 412 (N-benzoylstaurosporine), CGP41251 that is a powerful selective inhibitor of the protein kinase C isoforms . The development of the molecular therapeutics has advanced rapidly and its application to CML has attained very positive results that should increase with th
Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
Valia Pavón Morán,Porfirio Hernández Ramírez,Juan Carlos Jaime Fagundo,Olga Agramonte Llanes
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2005,
Abstract: La leucemia mieloide crónica (LMC) fue la primera neoplasia en la que se pudo presentar un modelo de genotipo que sirviera de blanco a una terapia de acción molecular. La activación de múltiples vías de se ales de transducción en las células con el gen BCR- ABL favorece el incremento de la proliferación celular, interfiere en la apoptosis y perturba la interacción con la matriz extracelular y el estroma. La introducción del Imatinib en el tratamiento de la LMC ha modificado la evolución y pronóstico de la enfermedad. Cuando se compara con los regímenes basados en interferón e hidroxiurea, el imatinib ha demostrado un alto nivel de eficacia asociado con un número menor de reacciones adversas Chronic myeloid leukemia (CML) was the first neoplasia in which it was possible to present a model of genotype that served as a target for a molecular action therapy. The activation of multiple ways of transduction signals in the cells with the BCR-ABL gene favors the increase of the cellular proliferation, interferes the apoptosis, and perturbs the interaction with the extracellular matrix and the stroma. The introduction of Imatinib in the treatment of CML has modified the evolution and prognosis of this disease. Imatinib has proved to have a high level of efficiency associated with a smaller number of adverse reactions on being compared with the regimens based on interferon and hydroxyurea
Leucemia mieloide crónica: Actualización en Citogenética y Biología Molecular
Pavón Morán,Valia; Hernández Ramírez,Porfirio; Martínez Antu?a,Gisela; Agramonte Llanes,Olga; Jaime Fagundo,Juan Carlos; Bravo Regueiro,Jeny;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2005,
Abstract: chronic myeloid leukemia (cml) is a a chronic myeloproliferative syndrome of clonal nature, originated in the stem cell, that results in an excessive number of myeloid cells in all the maturation stages. it was the first malignat disease in which an acquired genetic abnormality was proved, and it is at present the best studied molecular model of leukemia. in the chronic myeloid leukemia, it is expressed the chromosal translocation t (9;22) (q34;q11), giving rise to the formation of the philadelphia (ph) chromosome. due to this translocation, 2 new hybrid genes are produced: bcr-abl in chromosome 22q- or ph chromosome, and the reciprocal gene abl-bcr in the derivative chromosome 9q+, which , although transcriptionally active, does not seem to play any functional activity in the disease. nowadays, the identification of the minimal residual disease by molecular methods is very important for the exact evaluation of the evolutive state of the disease
Detección y cuantificación de autoanticuerpos en los hematíes de pacientes con anemia hemolítica autoinmune con prueba de Coombs negativa
Bencomo Hernández,Antonio A; Alfonso Valdés,María Elena; ávila Cabrera,Onel M; Jaime Fagundo,Juan Carlos; Hernández Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2005,
Abstract: 18 patients, 15 adults and 3 children, with hemolytic anemia and suspicion of immune etiology were studied. a favorable response to prednisone was observed among them. all the patients had had negative results in the direct and indirect antiglobulin test (coombs). the blood specimens were applied the direct polybrene technique (dpt), the detection of antibodies in the eulate of the red cells by the microplaque technique (mp), and the quantification of autoantibodies associated with red cells by elisa. these patients accounted for 13.3 % of the total of aiha cases diagnosed. the direct polybrene test detected the antibodies in 5 cases (28 %), whereas mp tested positive in 11 patients (61 %), and elisa showed autoantibodies in all the patients. elisa revealed the presence of igg autoantibodies in 17 cases (94.4 %), of iga in 8 patients (44.4 %), and of igm in one case (5.5 %). in 10 patients (55.5 %), the quantification of igg autoantibodies behaved in a range from 200 to 460 molecules per red cell. in the rest, values over 900 molecules per red cell were obtained. the results demonstrated that elisa is particularly useful for the detection and quantification of autoantibodies in the red cells of the patients with coombs negative aiha, and that it provides a procedure for the immunohematological diagnosis of this entity
Actualización en trasplante de células progenitoras hematopoyéticas en pacientes pediátricos en los últimos 15 a?os
Dorticós-Balea,Elvira; Jaime-Fagundo,Juan C.; Pavón-Morán,Valia; Reboredo-Domínguez,Mercedes; Hernández-Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2011,
Abstract: in the past year 2010, it was commemorate the 25 anniversary of introduction in cuba of the bone marrow transplantation and its development has followed the sequence of the universal history of the hematopoietic transplantation. in present paper authors made reference to more important achievements over the past 15 years including the introduction of the transplantation with mobilized cell to peripheral blood. partial results of a comparative study of 2 groups of pediatric patients are showed; one received hematopoietic progenitor cells obtained from the bone marrow and other with cells mobilized to the peripheral blood by means of hematopoietic growth factors. other advances include: the introduction of non-myeloablation transplantation in 2002, the application of recombinant factors produced in cuba in the management of transplanted patients and the introduction of chimerism. different features related to histocompatibility are analyzed as well as the requirements to improve the transplantation results. it is indicated the contribution of the experience obtained with this procedure for the development of the regenerative medicine.
Células progenitoras hematopoyéticas de sangre de cordón umbilical
Morera-Barrios,Luz M; Jaime-Fagundo,Juan Carlos; Dorticós-Balea,Elvira; Ustáriz-García,Catalino; Hernández-Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2012,
Abstract: the umbilical cord blood (ucb) is a rich source of hematopoietic progenitor cells (hpc) for transplantation. here, we describe the history of using of ucb for hematopoietic transplantation and the need of obtaining informed consent for its conservation, storage and further use for these purposes. reference is made to the security for the receiver in terms of sample selection, epidemiological, obstetrical, and analytical requirements, as well as the quality of hematopoietic collection and processing for preservation, in addition to the advantages and disadvantages of its use in transplantation. finally, we address the importance of increasing the ucb banks, storing cph with antigenic representation compatible with ethnic minorities.
Relación entre hemólisis con la presencia y cuantificación de inmunoglobulinas en hematíes, en la anemia hemolítica autoinmune
Bencomo-Hernández,Antonio A.; Alfonso-Valdés,María E.; ávila-Cabrera,Onel M.; Espinosa-Martínez,Edgardo; Jaime-Fagundo,Juan C.; Hernández-Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2010,
Abstract: a group of 135 patients was studied: 111 adults and 24 children presenting hot autoimmune hemolytic anemia (haiha) the erythrocyte characterization and the number of immunoglobulin molecules by red blood cells was determined by elisa. in 51 patients the pattern of igg subclasses was investigated. the hemolysis intensity was classified by the hemoglobin concentration, the reticulocytes count and the figures of plasma haptoglobin. in patients presenting with high degree hemolysis igm autoantibodies were detected in combination with igg, iga isotypes. in cases only with the presence of igg, the number of molecules of autoantibodies by red blood cells was the determinant factor in hemolysis. there were not differences in relation to subclasses pattern. the severity of hemolysis in haiha is related to the coexistence of multiple immunoglobulins in red blood cells and especially of the igm.
Caracterización fenotípica de las células madre de médula ósea utilizadas en la terapia celular regenerativa
Macías-Abraham,Consuelo; del Valle-Pérez,Lázaro O; Baganet-Cobas,Aymara; Dorticós-Balea,Elvira; Jaime-Fagundo,Juan C; Lam-Díaz,Rosa M; Socarrás-Ferrer,Bertha B; Sánchez-Segura,Miriam; Marsán-Suárez,Vianed; Palma-Salgado,Lourdes; Hernández-Ramírez,Porfirio; Ballester-Santovenia,José M;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2011,
Abstract: regenerative medicine is a novel therapeutic method with broad potential for the treatment of various illnesses, based on the use of bone marrow (bm) stem cells, whose phenotypic characterization is limited. the paper deals with the expression of different cell membrane markers in mononuclear bm cells from 14 patients who underwent autologous cell therapy, obtained by medullary puncture and mobilization to peripheral blood, with the purpose of characterizing the different types of cells present in that heterogeneous cellular population and identifying the adhesion molecules involved in their adhesion. a greater presence was observed of adherent stem cells from the marrow stroma in mononuclear cells obtained directly from the bm; a larger population of cd90+ cells in mononuclear cells from cd34-/cd45- peripheral blood with a high expression of molecules cd44 and cd62l, which suggests a greater presence of mesenchymal stem cells (msc) in mobilized cells from the marrow stroma. the higher levels of cd34+ cells in peripheral blood stem cells with a low expression of molecules cd117- and dr- suggests the presence of hematopoietic stem cells, hemangioblasts and progenitor endothelial cells mobilized to peripheral circulation. it was found that mononuclear cells from both the bm and peripheral blood show a high presence of stem cells with expression of adhesion molecule cd44 (mmc marker), probably involved in their migration, settling and differentiation.
Page 1 /6635
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.